Juan Fernandez, MD
Nephrology · Miami, FLNPI 1568481620
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,506 of the $3,522 with a category attached, or 71.2%. 21 manufacturers reported payments, led by Baxter Healthcare at 38.1% of the total. Reporting peaked in 2019 at $1,912 and has fallen 94.1% since, to $112 in 2025.
Across 107 payments — averaging $32.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$1K
- AstraZeneca$368
- Amgen$357
- Otsuka America Pharmaceutical, Inc.$206
- GSK$181
- Travere Therapeutics, Inc.$139
- plus $928 from 15 others
Across 442 payments — averaging $5660.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$544K
- Boehringer Ingelheim$528K
- CSL Behring$520K
- Boehringer Ingelheim International GmbH$489K
- Akebia Therapeutics Inc$236K
- Vertex$88K
- plus $97K from 5 others
What the payments were for
- Travel & lodging$99728%
- Food & beverage$2,50671%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 10 | $1,343 |
| AstraZeneca | 20 | $368 |
| Amgen(2 entities) | 17 | $357 |
| Otsuka America Pharmaceutical, Inc. | 10 | $206 |
| GSK | 4 | $181 |
| Travere Therapeutics, Inc. | 3 | $139 |
| Bayer | 7 | $137 |
| OPKO Pharmaceuticals, LLC | 7 | $125 |
| Harrow Eye, LLC | 4 | $112 |
| Lilly USA, LLC | 2 | $92 |
| Fresenius USA Marketing, Inc. | 5 | $83 |
| Vifor Pharma, Inc. | 4 | $79 |
| Calliditas Therapeutics US Inc. | 3 | $69 |
| Johnson & Johnson | 3 | $46 |
| Ardelyx, Inc. | 2 | $45 |
| Organogenesis Inc. | 1 | $30 |
| Akebia Therapeutics Inc | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Sanofi | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,522 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 75 | $47,401 |
| LokelmaSodium Zirconium Cyclosilicate | 72 | $43,486 |
| RayaldeeCalcifediol | 14 | $33,059 |
| ProcritEpoetin Alfa | 45 | $31,118 |
| Paricalcitol | 247 | $24,184 |
| VeltassaPatiromer Calcium Sorbitex | 32 | $23,847 |
| VelphoroSucroferric Oxyhydroxide | 11 | $19,060 |
| ProsolParenteral Amino Acid 20% No.1 | 91 | $14,137 |
| AuryxiaFerric Citrate | 14 | $14,092 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 59 | $13,689 |
| Sevelamer Carbonate | 40 | $9,141 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $8,417 |
| ClinisolParenteral Amino Acid 15% No.5 | 28 | $4,946 |
| Calcium Acetate | 45 | $2,620 |
| Cinacalcet Hcl | 33 | $2,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $368 | $90,886147 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $125 | $33,05914 claims |
| Johnson & JohnsonProcrit | $46 | $31,11845 claims |
| Fresenius USA Marketing, Inc.Velphoro | $83 | $19,06011 claims |
| Akebia Therapeutics IncAuryxia | $29 | $14,09214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.
Other nephrology in Miami
- Gabriel ContrerasMiami$133K
- Alessia FornoniMiami$97K
- Jonathan da CostaMiami$74K
- Yelena DrexlerMiami$43K
- Jochen ReiserMiami$43K
- Alba Gonzalez-OchoaMiami$39K
- Jorge BusseMiami$28K
- Loay SalmanMiami$14K
- David RothMiami$12K
- Arvind MadanOrlando$943K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.